Clinical Rheumatology

, Volume 30, Issue 10, pp 1325–1331 | Cite as

Lipid profile in Tunisian patients with rheumatoid arthritis

  • Saoussen Hassen Zrour
  • Fadoua Hassine Neffeti
  • Nabil Sakly
  • Mahbouba Jguirim
  • Wided Korbaa
  • Mohamed Younes
  • Ismail Bejia
  • Mongi Touzi
  • Najjar Mohamed Fadel
  • Naceur Bergaoui
Original Article


This study aims to assess the prevalence of dyslipidaemia in Tunisian patients with active RA and to investigate the clinical and biological associated factors. A cross-sectional study was conducted on 92 unselected patients with active RA (77 females and 15 males, aged 49.1 ± 12.5 years) and 82 healthy subjects (68 females and 14 males, aged 50.8 ± 13.3 years). We recorded the patients' characteristics and the results of a lipid profile test (total cholesterol, TC; high-density lipoprotein cholesterol, HDL-c; low-density lipoprotein cholesterol, LDL-c; triglyceride, TG; lipoprotein (a), Lp (a); apolipoprotein A-1, apo A-1 and apolipoprotein B, apo B). In comparison to the control group, RA patients showed a higher prevalence of associated dyslipidaemia (95.7% versus 65.9% of cases, p < 0.001). Sera of patients showed higher TC (4.86 ± 1.07 versus 3.98 ± 0.73 mmol/L, p < 0.001), LDL-c (3.49 ± 0.98 versus 1.99 ± 0.62 mmol/L, p < 0.001), Lp (a) (288.04 ± 254.59 versus 187.94 ± 181.37 mmol/L, p = 0.004) and lower HDL-c (0.66 ± 0.24 versus 1.12 ± 0.3 mmol/L, p < 0.001). TC/HDL-c, LDL-c/HDL-c and non-HDL-c/HDL-c were also higher in RA patients; they were 8.24 ± 3.20 versus 3.76 ± 1.26 (p < 0.001), 5.91 ± 2.48 versus 1.92 ± 0.99 (p < 0.001) and 7.24 ± 3.20 versus 2.76 ± 1.26 (p < 0.001), respectively. Apo A-1 was correlated to Lp (a) (r = 0.291, p = 0.005). Corticoid dose was not associated to dyslipidaemia, but in multiple regression models, corticoid dose may be negatively related to some atherogenic markers, in particular non-HDL-c. Tunisian patients with markedly active RA experience substantially reduced serum HDL-c and increased TC, LDL-c and Lp (a) concentrations as well as increased TC/HDL-c, LDL-c/HDL-c and non-HDL-c/HDL-c ratios.


Atherogenic index Cholesterol HDL cholesterol LDL cholesterol Lipoprotein (a) Rheumatoid arthritis Triglyceride 





  1. 1.
    Soubrier M, Dougados M (2006) Athérome et polyarthrite rhumatoïde. Rev Med Int 27:125–136CrossRefGoogle Scholar
  2. 2.
    Nurmohamed MT (2007) Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vasc Health Risk Manag 3:845–852PubMedGoogle Scholar
  3. 3.
    Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A et al (2008) Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 196:756–763PubMedCrossRefGoogle Scholar
  4. 4.
    Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N et al (2005) Accelerated atherosclerosis in autoimmune rheumatic disease. Circulation 112:3337–3347PubMedCrossRefGoogle Scholar
  5. 5.
    Ku IA, Imboden JB, Hsue PY, Ganz P (2009) Rheumatoid arthritis a model of systemic inflammation driving atherosclerosis. Circ J 73:977–985PubMedCrossRefGoogle Scholar
  6. 6.
    Assous N, Touzé E, Meune C, Kahan A, Allanore Y (2007) Morbimortlité cardiovasculaire au cours de la polyarthrite rhumatoïde: étude de cohorte hospitalière monocentrique française. Rev Rhum 74:72–78CrossRefGoogle Scholar
  7. 7.
    García-Gómez C, Nolla JM, Valverde J, Gómez-Gerique JA, Castro MJ, Pintó X (2009) Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis. J Rheumatol 36:1365–1370PubMedCrossRefGoogle Scholar
  8. 8.
    Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 256:2835–2838PubMedCrossRefGoogle Scholar
  9. 9.
    Walldius G, Jungner I (2006) The apo B/apo A-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid – lowering therapy a review of the evidence. J Intern Med 259:493–519PubMedCrossRefGoogle Scholar
  10. 10.
    Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA, National Lipid Association Taskforce on Non-HDL Cholesterol (2008) The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol 2:267–73PubMedCrossRefGoogle Scholar
  11. 11.
    Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW (2004) Cardiovascular risk factors in women with ant without rheumatoid arthritis. Arthritis Rheum 50:3444–3449PubMedCrossRefGoogle Scholar
  12. 12.
    Boers M, Nurmohamed MT, Doelman CJ, Lard LR, Verhoeven AC, Voskuyl AE et al (2003) Influence of glucocorticoïd and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62:842–845PubMedCrossRefGoogle Scholar
  13. 13.
    Park YB, Hk C, Kim MY, Lee WK, Song J, Kim DK et al (2002) Effect of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis a prospective study. Am J Med 113:188–193PubMedCrossRefGoogle Scholar
  14. 14.
    Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH et al (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701–1704PubMedGoogle Scholar
  15. 15.
    Van Halm VP, Nielen MMJ, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE et al (2007) Lipids and inflammation: serial measurement of the lipid profile of blood donors who later develop RA. Ann Rheum Dis 66:184–188PubMedCrossRefGoogle Scholar
  16. 16.
    Dursunoglu D, Evrengül H, Polat B, Tanriverdi H, Cobankara V, Kaftan A et al (2005) Lp (a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relation ship to inflammation. Rheumatol Int 25:241–245PubMedCrossRefGoogle Scholar
  17. 17.
    Lee YH, Choi SJ, Ji JD, Seo HS, Song GG (2000) Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 19:324–325PubMedCrossRefGoogle Scholar
  18. 18.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  19. 19.
    Fransen J, van Riel PL (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23:S93–S99PubMedGoogle Scholar
  20. 20.
    Steinbroker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659–662Google Scholar
  21. 21.
    Dessein PH, Christian BF, Solomon A (2009) Which are the determinants of dyslipidemia in rheumatoid arthritis and does socioeconomic status matter in this context? J Rheumatol 36:1357–1361PubMedCrossRefGoogle Scholar
  22. 22.
    Burger D, Dayer JM (2002) High-density lipoprotein-associated apolipoprotein A-1: the missing link between infection and chronic inflammation? Autoimmun Rev 1:111–117PubMedCrossRefGoogle Scholar
  23. 23.
    Sfar S, Laporte F, Braham H, Jawed A, Amor S, Kerkeni A (2010) Influence of dietary habits, age and gender on plasma fatty acids levels in a population of healthy Tunisian subjects. Exp Gerontol. doi: 10.1016/j.exerg.2010.05.003 PubMedGoogle Scholar
  24. 24.
    Navarro-Cano G, Del Rincon I, Pogosian S, Roldan JF, Escalante A (2003) Association of mortality with disease severity in rheumatoïd arthritis, independent of comorbidity. Arthritis Rheum 48:2425–2433PubMedCrossRefGoogle Scholar
  25. 25.
    Wolfe F, Michaud K, Gefeller O, Choi HK (2003) Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 48:1530–1542PubMedCrossRefGoogle Scholar
  26. 26.
    Dessein PH, Joffe BI (2006) When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J Rheumatol 33:201–203PubMedGoogle Scholar
  27. 27.
    Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126PubMedCrossRefGoogle Scholar
  28. 28.
    Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK 3rd, Roux-Lombard P et al (2001) Apolipoprotein A-1 inhibits the production of IL1-β and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97:2381–2389PubMedCrossRefGoogle Scholar
  29. 29.
    Libby P (2008) Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 121:S21–S31PubMedCrossRefGoogle Scholar
  30. 30.
    Mak A, Ho RC-M, Tan JY-S, Teng GG, Lahiri M, Lateef A et al (2009) Atherogenic serum lipid profile is an independant predictor for gouty flares in patients with gouty arhropathy. Rheumatology 48:262–265PubMedCrossRefGoogle Scholar
  31. 31.
    Hulthe J, Fagerberg B (2002) Circulated oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Aterioscler Thromb Vasc Biol 22:1162–1167CrossRefGoogle Scholar
  32. 32.
    Fraser DA, Thoen J, Rustan AC, Forre O, Kjeldsen-Kragh (1999) Changes in plasma free fatty acid concentrations in rheumatoid arthritis patients during fasting and their effects upon T-lymphocyte proliferation. Rheumatology 38:948–952PubMedCrossRefGoogle Scholar
  33. 33.
    Hafstrom I, Rohani M, Denerberg S, Wornert M, Jogestrand T, Frostegard J (2007) Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis. A randomized study. J Rheumatol 34:1810–1816PubMedGoogle Scholar
  34. 34.
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodringuez T, Martin J, Llorca J (2008) Carotid intima-media thickness and endothelial function: useful surrogate markers for establishing cardiovascular risk in patients with inflammatory rheumatic disease. Arthritis Res Ther 10:403PubMedCrossRefGoogle Scholar
  35. 35.
    Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-diaz E, Testa A, Garcia-Porrua C et al (2007) Endothelial dysfonction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57:287–293PubMedCrossRefGoogle Scholar
  36. 36.
    Veldhuyzen Van Zanter JJCS, Kites GD (2008) Inflammation, carotid intima-media thickness and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 10:102–103CrossRefGoogle Scholar
  37. 37.
    Svenson KL, Lithell H, Hallgren R, Vessby B (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides II. Effects of anti-inflammatory and disease modifying drug treatment. Arch Intern Med 147:1917–1920PubMedCrossRefGoogle Scholar
  38. 38.
    Kremers HM, Reinalda MS, Crowson CS, Davis JM, Hunder GG, Gabriel SE (2007) Glucocorticoïds and cardiovascular and cerebrovascular events in polymyalgie rheumatica. Arthritis Rheum 57:279–286CrossRefGoogle Scholar
  39. 39.
    Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK et al (2010) Recommendations EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331PubMedCrossRefGoogle Scholar
  40. 40.
    McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I et al (2004) Trial of atrovastatin in rheumatoid arthritis (TARA): double –blind, randomised placebo-controlled trial. Lancet 363:2015–2021PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2011

Authors and Affiliations

  • Saoussen Hassen Zrour
    • 1
  • Fadoua Hassine Neffeti
    • 2
  • Nabil Sakly
    • 3
  • Mahbouba Jguirim
    • 1
  • Wided Korbaa
    • 1
  • Mohamed Younes
    • 1
  • Ismail Bejia
    • 1
  • Mongi Touzi
    • 1
  • Najjar Mohamed Fadel
    • 2
  • Naceur Bergaoui
    • 1
  1. 1.Rheumatology DepartmentMonastir Teaching HospitalMonastirTunisia
  2. 2.Biochemistry DepartmentMonastir Teaching HospitalMonastirTunisia
  3. 3.Immunology DepartmentMonastir Teaching HospitalMonastirTunisia

Personalised recommendations